Citadel Advisors’s Columbia Research Enhanced Value ETF REVS Stock Holding History
Bought
Maintained
Sold
Other funds holding REVS
USCWA
NA
SPIA
RA
WIA
Citadel Advisors's REVS Position: Q1 2026 in Review
Citadel Advisors sold out of Columbia Research Enhanced Value ETF (REVS) in Q1 2026, closing a stake of 11,016 shares — an estimated $312K sold.
Citadel Advisors first reported a position in REVS in Q3 2022 and held it in 7 quarters. The position peaked at $520K in Q2 2025. 37 funds tracked by Wall St. Rank hold REVS as of Q1 2026.
- Citadel Advisors reported no remaining Columbia Research Enhanced Value ETF position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 11,016 Columbia Research Enhanced Value ETF shares in Q1 2026, an estimated $312K.
- Citadel Advisors first reported a position in Columbia Research Enhanced Value ETF in Q3 2022 and held it in 7 quarters.
- Citadel Advisors's Columbia Research Enhanced Value ETF position peaked at $520K in Q2 2025.
- 37 funds tracked by Wall St. Rank held Columbia Research Enhanced Value ETF as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.